Eli Lilly and Novo Nordisk Set to Compete in Oral Obesity Drug Arena

Eli Lilly and Novo Nordisk are gearing up to advance their competition into a new dimension of weight-loss treatment: oral medications.

Both pharmaceutical giants have plans to debut their weight-loss tablets in the United States in the coming year, contingent upon obtaining regulatory clearance. These daily medications have the potential to expand the use of GLP-1 receptor agonists, which are typically associated with weekly injectables.

However, when Lilly's oral medication demonstrated lower than anticipated weight reduction, it prompted questions regarding the broader acceptance of these oral solutions and which company will lead this segment.

Upcoming Comparisons and Expectations

Detailed insights will become available shortly as Lilly conducts a comparative study between its oral drug and Novo's. This study, as noted by Dan Skovronsky, Lilly's Chief Scientific Officer, primarily focuses on how well these drugs reduce blood sugar in patients with Type 2 diabetes, alongside their capacity for weight loss.

"Embarking on this comprehensive evaluation indicates our confidence in orforglipron's performance against oral semaglutide," Skovronsky stated.

Assessing Drug Efficacy

He warned against drawing conclusions from different studies not designed for direct product comparison, as Novo's pill appears more potent with fewer dropouts. Martin Holst Lange, Novo's Chief Scientific Officer, mentioned that the outcomes speak for themselves.

Novo's upcoming pill is an oral adaptation of its existing Wegovy injection, while Lilly is introducing a novel drug, orforglipron, distinct from its injectable Zepbound, which is noted for aiding over 20% body weight loss.

Market Dynamics and Future Predictions

Neither Novo’s nor Lilly's pills match the effectiveness of Zepbound. At its top dosage, orforglipron achieves roughly a 12% weight decline, whereas oral semaglutide gets about a 17% reduction, triggering discussions on the appeal of less effective pills.

Despite these differences, analysts project oral options to significantly contribute to the obesity drug market, possibly capturing 20% of an $80 billion market by 2030 according to Evaluate's projections.

Skovronsky envisions that pills could potentially become the primary treatment method worldwide, outperforming injectable solutions. He highlighted that patients prioritize considerations like supply chain and ease over the magnitude of weight loss, positing that orforglipron holds potential advantages.

Logistical Considerations and Market Impact

Evan Seigerman from BMO Capital Markets noted that orforglipron, being a small molecule, simplifies production when compared to peptides used in injections and Novo's pill. Additionally, it doesn’t have the same dietary restrictions post-ingestion that Novo's pill does.

Seigerman states, "Considering orforglipron's lack of food effect and simpler manufacturing, it stands favorable, though Novo Nordisk's new leader Mike Doustdar is likely to aggressively ensure a successful product rollout."

Following results from Lilly's trial, Seigerman adjusted his market share projections slightly in favor of oral semaglutide. Analysts have lowered their 2032 revenue expectations for orforglipron by approximately $4.5 billion since earlier in the year, with current projections at $14.56 billion.

Anticipating Future Developments

Skovronsky acknowledges the unpredictability of future market trends compared to scientific predictions.

"Our scientific forecasts were accurate. We developed an oral treatment with comparable safety, tolerance, and effectiveness to injectable GLP-1s," he said. "The scientific components were predictable; let's observe how market tendencies unfold."